Profile

Sarah Walsh
Title: Dr
First Name: Sarah
Surname: Walsh
Position: Senior Research Fellow
Telephone: +44 (0) 1224 262562
Email:
Linkedin: LinkedIn Icon https://uk.linkedin.com/in/sarah-walsh-b4693636

Sarah Walsh is a Senior Research Fellow within the Centre for Cardiometabolic Health Research.

Academic Background

  • PhD in Cardiovascular Pharmacology - Robert Gordon University (2007)
  • BSc (Hons) in Physiology - National University of Ireland, Galway (2002)

Research Interests

Research interests include investigating the cardiovascular role of novel G protein coupled receptors and their participation in cardiac dysfunction, the effects of metabolic syndrome on cardiac structure and function, and maladaptive cardiovascular remodelling in complicated pregnancies.

Current Research

  • Vascular role of frizzled receptor 2 (FZD2) in hypertension
  • Secreted frizzled-related proteins (sFRPs) and their role in heart failure
  • Interaction of GPR55 and adrenoceptors in the cardiovascular system
  • Cannabinoids and cardioprotection

Funding

  • sFRPs as a novel modulator of diastolic heart failure. Medical Research Council (UK, United Kingdom) Grant: MR/P016278/1 (2017-2021) £98,431
  • GPR55 as a novel regulator of cardiac adrenoceptor activity. British Pharmacological Society (UK, United Kingdom) Grant: IPF Pump Priming Grant 13/14 (2013-2014) £10,000
  • Studies to determine the role of the endogenous GPR55 ligand lyosohposphatidylinositol (LPI) in cardioprotection. Tenovus (UK, United Kingdom) Grant: G11//G15 (2012-2013) £8,725

Professional Memberships

Member of the:

  • British Pharmacological Society
  • International Society for Heart Research
  • British Society for Cardiovascular Research
  • Scottish Cardiovascular Forum

External / Professional Roles

  • Manuscript reviewer for Science Translational Medicine, British Journal of Pharmacology, Hypertension, American Journal of Hypertension, Vascular Pharmacology, Vascular Medicine, and Reproductive Sciences.
  • Grant reviewer for the William Harvey International Translational Research Academy (WHRI-ACADEMY) and the British Council Researcher Links program.
  • Editorial board member for Pharmacology Research & Perspectives.
  • Member of both the British Pharmacological Society Membership & Awards committee and the Scottish Cardiovascular Forum committee.

Publications

  • Walsh SK, Hepburn CY, Keown OP, Åstrand A, Lindblom A, Ryberg E, Hjorth S, Leslie SJ, Greasley PJ, Wainwright CL (2015). Pharmacological profiling of the haemodynamic effects of cannabinoid ligands: A combined in vitro and in vivo approach. Pharmacol Res Perspect 3(3): e00143. doi:10.1002/prp2.143
  • Walsh SK, Hector EE, Andréasson A-C, Jönsson-Rylander A-C, Wainwright CL (2014). GPR55 deletion in mice leads to age-related ventricular dysfunction and impaired adrenoceptor-mediated inotropic responses. PLoS ONE 9(10): e108999. doi:10.1371/journal.pone.0108999
  • McCarthy FP, Delany AC, Kenny LC, Walsh SK (2013). PPAR-γ - a possible drug target for complicated pregnancies. Br J Pharmacol 168:1074-1085
  • Walsh SK, English FA, Crocker IP, Johns EJ, Kenny LC (2012). Contribution of poly(ADP-ribose) polymerase to endothelial dysfunction and hypertension in a rat model of pre-eclampsia. Br J Pharmacol 166(7):2109-2116
  • English FA, McCarthy FP, Andersson IJ, Stanley JL, Davidge ST, Baker PN, Walsh SK, Kenny LC (2012). Administration of the PARP inhibitor PJ34 ameliorates the impaired vascular function associated with eNOS-/- mice. Reprod Sci 19(8):806-813
  • McCarthy FP, Kingdom J, Kenny LC, Walsh SK (2011). Animal models of preeclampsia; uses and limitations. Placenta 32(6):413-419
  • McCarthy FP, Drewlo S, English FA, Kingdom J, Johns EJ, Kenny LC, Walsh SK (2011). Evidence implicating peroxisome proliferator activated receptor gamma in the pathogenesis of preeclampsia. Hypertension 58(5):882-887
  • Horgan RP, Broadhurst DI, Walsh SK, Dunn WB, Brown M, Dekker G, North RA, Kell DB, Baker PN, Kenny LC (2011). Metabolic profiling uncovers an early phenotypic signature of Small for Gestational Age. J Proteome Res 10(8):3660-3673
  • McCarthy FP, Drewlo S, Kingdom J, Johns EJ, Walsh SK, Kenny LC (2011). Peroxisome proliferator activated receptor gamma as a potential therapeutic target in the treatment of preeclampsia. Hypertension 58(2):280-286
  • Walsh SK, Hepburn CY, Kane KA, Wainwright CL (2010). Acute administration of cannabidiol suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol 160(5):1234-1242
  • Walsh SK, English FA, Johns EJ, Kenny LC (2009). Plasma-mediated vascular dysfunction in the reduced uterine perfusion pressure (RUPP) rat model of preeclampsia: A microvascular characterization. Hypertension 54(2):345-351
  • Walsh SK, Kane KA, Wainwright CL (2009). Mast cells, peptides and cardioprotection – an unlikely marriage? Auto & Autacoid Pharmacol 29(3):73-84
  • Walsh SK, Kane KA, Wainwright CL (2009). Mast cell degranulation – a mechanism for the antiarrhythmic effect of endothelin-1? Br J Pharmacol 157(5):716-723